Diabetic Gastroparesis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Diabetic Gastroparesis – Pipeline Review, H1 2020’, provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis

– The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlfaSigma SpA

Allergan Plc

Atlantic Healthcare Plc

Bird Rock Bio Inc

Censa Pharmaceuticals Inc

CinRx Pharma LLC

ETX Pharma Inc

Evoke Pharma Inc

Johnson & Johnson

Takeda Pharmaceutical Co Ltd

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Gastroparesis – Overview

Diabetic Gastroparesis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Gastroparesis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Gastroparesis – Companies Involved in Therapeutics Development

AlfaSigma SpA

Allergan Plc

Atlantic Healthcare Plc

Bird Rock Bio Inc

Censa Pharmaceuticals Inc

CinRx Pharma LLC

ETX Pharma Inc

Evoke Pharma Inc

Johnson & Johnson

Takeda Pharmaceutical Co Ltd

Vanda Pharmaceuticals Inc

Diabetic Gastroparesis – Drug Profiles

CIN-102 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNSA-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-101 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metoclopramide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nimacimab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

renzapride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-906 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velusetrag – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Gastroparesis – Dormant Projects

Diabetic Gastroparesis – Discontinued Products

Diabetic Gastroparesis – Product Development Milestones

Featured News & Press Releases

Jan 21, 2020: FDA accepts Evoke Pharma’s NDA resubmission for Gimoti

Dec 20, 2019: Evoke resubmits Gimoti new drug application to FDA

Sep 17, 2019: Evoke Pharma completes manufacturing of commercial scale registration batches of Gimoti

Aug 08, 2019: Evoke Pharma to resubmit Gimoti NDA based on FDA Meeting minutes and announces second quarter 2019 financial results

Jun 27, 2019: Evoke Pharma requests Type A FDA meeting to plan for resubmission of Gimoti NDA

May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis

Apr 02, 2019: Evoke Pharma receives complete response letter and recommendations to address deficiencies from FDA for Gimoti NDA

Jan 07, 2019: Evoke Pharma signs commercial and financial agreement for its Lead Product Gimoti in the U.S. with Novos Growth Partners

Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis

Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018

Aug 16, 2018: Evoke Pharma’s Gimoti NDA Accepted for FDA Review

Jun 04, 2018: Evoke Announces FDA Submission of New Drug Application for Gimoti

May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis

May 10, 2018: Evoke Granted Gender Specific Patent for Gimoti in Mexico

Apr 30, 2018: Evoke Granted First Gender Specific Patent for Gimoti

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Gastroparesis, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Diabetic Gastroparesis – Pipeline by AlfaSigma SpA, H1 2020

Diabetic Gastroparesis – Pipeline by Allergan Plc, H1 2020

Diabetic Gastroparesis – Pipeline by Atlantic Healthcare Plc, H1 2020

Diabetic Gastroparesis – Pipeline by Bird Rock Bio Inc, H1 2020

Diabetic Gastroparesis – Pipeline by Censa Pharmaceuticals Inc, H1 2020

Diabetic Gastroparesis – Pipeline by CinRx Pharma LLC, H1 2020

Diabetic Gastroparesis – Pipeline by ETX Pharma Inc, H1 2020

Diabetic Gastroparesis – Pipeline by Evoke Pharma Inc, H1 2020

Diabetic Gastroparesis – Pipeline by Johnson & Johnson, H1 2020

Diabetic Gastroparesis – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Diabetic Gastroparesis – Pipeline by Vanda Pharmaceuticals Inc, H1 2020

Diabetic Gastroparesis – Dormant Projects, H1 2020

Diabetic Gastroparesis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Diabetic Gastroparesis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports